Written by cpm from CPM Magazine
Download PDF The ‘Central Dogma’ is the process by which the instructions in DNA are converted into a functional product and understanding how biostimulants effect this process in plants could help answer how they work. CPM finds out more. The initial effect of Bio 20 on gene expression is very rapid. By Lucy de la Pasture So how does it work? That’s the question that’s been asked about biostimulant products for decades. Advances in molecular biology and ‘omics’ technologies mean that this question can be answered with a degree of certainty for the first time. Up until very recently it’s been the results of field trials and glasshouse studies that have furthered the understanding of benefits biostimulant products can bring, explains David Booty, technical development manager at Omex. “One of the problems with biostimulant products is that they perform better in some circumstances than in others and that’s made it very difficult to understand how to get the best out of them in the field.” To help bridge this gap in knowledge, Omex commissioned Novogene in Cambridge to carry out an RNA-sequencing transcriptomics study using its globally best-selling biostimulant/nutritional product, Bio 20. “Genetic analysis techniques have become faster and more affordable…
The post Research Briefing – RNA holds the answer appeared first on cpm magazine.
Continue reading on CPM website...
If you are enjoying what you read then why not considering subscribing here: http://www.cpm-magazine.co.uk/subscribe/
Download PDF The ‘Central Dogma’ is the process by which the instructions in DNA are converted into a functional product and understanding how biostimulants effect this process in plants could help answer how they work. CPM finds out more. The initial effect of Bio 20 on gene expression is very rapid. By Lucy de la Pasture So how does it work? That’s the question that’s been asked about biostimulant products for decades. Advances in molecular biology and ‘omics’ technologies mean that this question can be answered with a degree of certainty for the first time. Up until very recently it’s been the results of field trials and glasshouse studies that have furthered the understanding of benefits biostimulant products can bring, explains David Booty, technical development manager at Omex. “One of the problems with biostimulant products is that they perform better in some circumstances than in others and that’s made it very difficult to understand how to get the best out of them in the field.” To help bridge this gap in knowledge, Omex commissioned Novogene in Cambridge to carry out an RNA-sequencing transcriptomics study using its globally best-selling biostimulant/nutritional product, Bio 20. “Genetic analysis techniques have become faster and more affordable…
The post Research Briefing – RNA holds the answer appeared first on cpm magazine.
Continue reading on CPM website...
If you are enjoying what you read then why not considering subscribing here: http://www.cpm-magazine.co.uk/subscribe/